home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Bio-Techne Corp - Common Stock (NQ:TECH)

55.54 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bio-Techne Corp - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

RBC Capital Maintains Sector Perform Rating for Bio-Techne: Here's What You Need To Know ↗

February 02, 2024

Via Benzinga

3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 ↗

January 21, 2024

These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024.

Via InvestorPlace

Expert Ratings for Bio-Techne ↗

December 07, 2023

Via Benzinga

Advancing with Stability: Bio-Techne Benefits Investors with Growing Earnings and Stable Payouts ↗

November 24, 2023

By the close of today, November 24, 2023, Bio-Techne (NASDAQ:TECH) will issue a dividend payout of $0.08 per share, resulting in an annualized dividend yield of 0.56%. Only those investors who owned...

Via Benzinga

Earnings Preview: Bio-Techne ↗

October 30, 2023

Via Benzinga

3 AI Stock-Split Stocks to Buy Now ↗

October 25, 2023

Traditional stock splits don’t happen very often. AI stock splits are even rarer. Here are three possibilities.

Via InvestorPlace

Topics Artificial Intelligence

Bio-Techne's Ex-Dividend Date Is Thursday, Here's What You Need To Know ↗

August 14, 2023

Via Benzinga

Nurturing Growth: Bio-Techne Supports Investors with Growing Earnings ↗

August 08, 2023

Via Benzinga

This Favorable Sign Appears On Bio-Techne's Chart ↗

May 31, 2023

Via Benzinga

Earnings Scheduled For February 1, 2024 ↗

February 01, 2024

Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...

Via Benzinga

Earnings Outlook For Bio-Techne ↗

January 31, 2024

Via Benzinga

Earnings Scheduled For October 31, 2023 ↗

October 31, 2023

Companies Reporting Before The Bell • BBVA (NYSE:BBVA) is likely to report earnings for its third quarter. • BP (NYSE:BP) is expected to report quarterly earnings at $1.37 per share on revenue of...

Via Benzinga

3 Healthcare Stocks to Keep an Eye On ↗

October 03, 2023

These three lesser-known healthcare companies have strong growth potential.

Via The Motley Fool

3 Healthcare Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 23, 2023

The beauty of healthcare stocks is that they tend to do well in most economic conditions because you can’t live without them.

Via InvestorPlace

What 4 Analyst Ratings Have To Say About Bio-Techne ↗

May 04, 2023

Via Benzinga

Bio-Techne: Q3 Earnings Insights ↗

May 03, 2023

Via Benzinga

Thursday Is Your Last Chance To Buy Bio-Techne Before The Dividend Payout ↗

February 07, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

October 02, 2023

On Monday, 369 companies set new 52-week lows.

Via Benzinga

Life Science Firm Bio-Techne's Success Formula: Astute Acquisitions Offering Transformation ↗

August 28, 2023

William Blair has initiated coverage on coverage of Bio-Techne Corp (NASDAQ: TECH) with a

Via Benzinga

Analyst Expectations for Bio-Techne's Future ↗

February 03, 2023

Via Benzinga

Earnings Outlook For Bio-Techne ↗

February 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗

August 28, 2023

Via Benzinga

3 Biotech Stocks to Buy Before the Breakout ↗

July 28, 2023

Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch.

Via InvestorPlace

Bio-Techne's Acquisition of Lunaphore Expands Its Spatial Biology Offerings ↗

June 22, 2023

Bio-Techne Corporation (NASDAQ: TECH) has agreed to acquire Lunaphore Inc with

Via Benzinga

Lunaphore to Get Acquired by Bio-Techne

June 22, 2023

From Lunaphore

Via Business Wire

Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation ↗

June 20, 2023

RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22,

Via Benzinga

This Analyst With 83% Accuracy Rate Sees Around 11% Upside In Texas Roadhouse - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts ↗

May 08, 2023

U.S stocks closed higher on Friday, with the Dow Jones jumping more than 500 points during the session.

Via Benzinga

7 Biotech Stocks That Could Cure Your Portfolio Woes ↗

April 19, 2023

If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.

Via InvestorPlace

5 Cheapest Health Care Stocks You Should Think About ↗

January 27, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

5 Health Care Stocks That Are Diving - And May Rally ↗

January 19, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com